How Johnson & Johnson positions its newly acquired RiPTAC platform and prostate program from Halda

The payer and oncology-community reaction to Poherdy, the first interchangeable biosimilar to Perjeta

Continued fallout from the NIH grant-termination findings, which disrupted 3.5 percent of NIH-funded trials

J&J acquires Halda for about $3.05B
The deal brings in Halda’s RiPTAC targeted cell-death platform and lead prostate cancer candidate, extending J&J’s precision oncology depth. 👉 Read more

FDA approves Poherdy, first interchangeable Perjeta biosimilar
Developed by Henlius and Organon, Poherdy becomes the first interchangeable biosimilar to Perjeta in HER2-positive breast cancer, initiating the next phase of HER2 pricing pressure. 👉 Read more

Nuvalent hits pivotal bar with neladalkib in ALK+ NSCLC
The ALK inhibitor delivered durable responses in previously treated patients, with many lasting ≥12 months, strengthening Nuvalent’s case as a next-generation TKI contender. 👉 Read more

Halda deal signals rising interest in non-ADC targeted cell-death platforms
RiPTACs attract attention for their precision and potential resistance advantages. 👉 Read more

Artios raises $115M to advance DNA damage response (DDR) programs
The round supports alnodesertib and SLFN11-directed assets as DDR continues drawing sustained capital. 👉 Read more

Captain T Cell secures ~€20M to advance next-generation TCR-T
Funding and grants move its autologous and allogeneic solid-tumor programs into and toward first-in-human studies. 👉 Read more

CAR T enters autoimmune disease with new UCI lupus trial
A formal step toward translating early academic remission data into a structured clinical program. 👉 Read more

Silo Pharma preparing PTSD IND
SPC-15 advances with Allucent support as CNS and trauma-related indications expand their development footprint. 👉 Read more

Cincinnati Children’s expands cell and gene therapy (CGT) infrastructure
The planned facility boosts trial capacity and translational manufacturing. 👉 Read more

J&J’s $3.05B Halda acquisition strengthens its oncology pipeline
A mid-range M&A asset that reinforces big pharma’s emphasis on targeted mechanisms. 👉 Read more

Synchron raises $200M to accelerate its BCI neurotech platform
The round supports commercial runway for its minimally invasive brain–computer interface system and positions Synchron alongside robotics and AI-enabled medtech growth stories. 👉 Read more

Bambusa completes Series A-2 to push bispecific I&I assets
Funds IND-enabling work for BBT003/004. 👉 Read more

Invivyd raises ~$125M; TELA Bio completes $13M offering
Both reinforce the constructive backdrop for targeted capital raises. 👉 Read more

NIH grant cuts disrupted 383 trials and more than 74,000 participants
A JAMA analysis highlighted $1.81B in terminated funding and disproportionate impacts in infectious disease and prevention. 👉 Read more

EU IVDR’s burden continues to slow diagnostic innovation
Industry leaders warn the regulation is elongating timelines and raising costs. 👉 Read more

FDA clarifies device QMSR future expectations
Aligns CGMP with ISO 13485 and defines implications for 2026 and beyond. 👉 Read more

Oncology dominated with a combined $3.05B buyout + $115M DDR + ~€20M TCR-T

First interchangeable Perjeta biosimilar expands HER2 competition

Neurotech and robotics momentum reinforced by Synchron’s $200M raise

AI-biotech and medtech-packaging forecasts show infrastructure acceleration

NIH funding volatility emerges as a real operational risk

M&A today: $3.05B

Oncology financings: $115M + ~€20M

NIH disruption: 383 trials, >74,000 participants, $1.81B in terminated grants

Sell-side coverage of Halda–J&J and Poherdy

Continued readthrough from Nuvalent’s pivotal data

Device updates around Arctx Cool Catheter and Modular’s Pivot study setup

XBI: ~114.8 (+0.7%)

IBB: ~165.3 (+0.6%)

Tone: Constructive on oncology M&A and pivotal data, with NIH instability creating a new macro overhang.